Table 1.
Key patient characteristics
| References | Country | Type | Indication | Diagnosis
|
Number of patients on golimumab | Gender
|
Age
|
Disease duration in years
|
Biologic-naive
|
|---|---|---|---|---|---|---|---|---|---|
| n (%) | Female, n (%) | Mean (SD) | Mean (SD) | n (%) | |||||
| Khalil and Tahami34 2012 | Canada | Admin | RA | 146 (100) | 146 | NR | NR | NR | NR |
| Dalén et al,33 2016 | Sweden | Admin | AS | 205 (27.2) | 754 | 440 (58.4) | 49.8 (15.6) | NR | 440 (100) |
| PsA | 155 (20.6) | ||||||||
| RA | 352 (46.7) | ||||||||
| Other | 44 (5.5) | ||||||||
| Hirano et al,40 2015 | Japan | Register | RA | 111 (100) | 111 | 93 (89.4) | 61.9 | 13.2 | NR (53.2) |
| Sato et al,20 2015 | Japan | Chart review | RA | 77 (100) | 77 | NR | 50.7 (14.4) | 11.0 (9.7) | NR (50.7) |
| Aaltonen et al,38 2016 | Finland | Register | RA | 195 (5.8) | 195 | NR (74a) | 55a,b | NR | NR |
| Saevarsdottir et al,35 2014 | Sweden | Register | RA | 849 (40) | 2,106 | NR (78) | 54b | 2.9–6.9c | NR (48) |
| PsA | 454 (22) | NR (50) | 48b | 6.1–7.0c | NR (46) | ||||
| AS | 303 (14) | NR (29) | 42b | 7.8–15.1c | NR (42) | ||||
| SpA | 242 (12) | NR (55) | 40b | 6.3–13.1c | NR (40) | ||||
| Other | 258 (12) | NR | NR | NR | NR | ||||
| Favalli et al,36 2016 | Italy | Register | RA | 677 (100) | 136 | NR (79.7a) | 54.3 (13.5)a | 8.9 (8.8)a | 85 (62.5) |
| Hayashi et al,43 2016 | Japan | Register | RA | 152 (100) | 152 | NR | NR | NR | 80 (52.6) |
| Manara et al,37 2016 | Italy | Register | RA | 180 (43.9) | 180 | NR (81.6) | 54.6 (13.6) | 9.5 (9.3) | 85 (47.2) |
| PsA | 110 (26.8) | 110 | NR (50.0) | 47.9 (12.8) | 7.9 (6.7) | 47 (42.7) | |||
| AS | 120 (29.3) | 120 | NR (43.3) | 45.2 (12.2) | 9.7 (10.0) | 51 (42.5) | |||
| Mourão et al,41 2016 | Portugal | Register | RA | 109 (100) | 109 | NR (86.3) | 55.5 (13.2) | 10 | 109 (100) |
| Rotar and Tomšič,39 2016 | Slovenia | Register | RA | 103 (34.2) | 103 | NR (76) | 59b | 6.8b | NR (79) |
| PsA | 76 (25.2) | 76 | NR (51) | 44b | 8.0b | NR (70) | |||
| AS | 122 (40.5) | 122 | NR (37) | 49b | 4.8b | NR (67) | |||
| Santo et al,42 2016 | Italy | Cohort | RA | 89 (21.4) | 89 | NR | NR | 8.1 (8) | 171 (41) |
| PsA | 180 (43.3) | 180 | NR | NR | 6.9 (6) | ||||
| Axial SpA | 147 (35.3) | 147 | NR | NR | 7.4 (7) |
Notes:
a
Multicenter prospective observational study;
b
Median;
c
Range across indications.
Abbreviations: AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; Axial SpA, axial spondyloarthritis; SD, standard deviation; NR, not reported.